MedPath

Evaluation of Patients Who Have Not Had Success With Zidovudine

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00001025
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine the relationship of viral susceptibility to zidovudine (AZT) and baseline viral load (as determined by plasma viremia and quantitative endpoint dilution). To determine the relationship between viral load and susceptibility during different antiretroviral therapy strategies. To correlate measures of viral load and short term clinical and laboratory markers (such as weight, CD4 count, p24 antigenemia, and beta2 microglobulin) on the different therapy arms.

High-grade resistance to AZT has been detected in HIV isolates from approximately 25 percent of individuals with AIDS who received AZT for at least 1 year. To elucidate the clinical significance of in vitro AZT resistance, it is necessary to distinguish between clinical failure caused by AZT resistance and clinical decompensation caused by other factors.

Detailed Description

High-grade resistance to AZT has been detected in HIV isolates from approximately 25 percent of individuals with AIDS who received AZT for at least 1 year. To elucidate the clinical significance of in vitro AZT resistance, it is necessary to distinguish between clinical failure caused by AZT resistance and clinical decompensation caused by other factors.

One hundred-twenty patients who have been receiving AZT for at least 1 year are randomized to 1) continue with AZT, 2) switch to treatment with didanosine at 1 of 2 doses, or 3) receive both AZT and ddI. Treatment is given for 16 weeks, with a possible extension to 32 weeks. Patients are followed at weeks 2, 4, 8, 12, and 16. For analysis purposes only, patients are stratified according to degree of susceptibility of HIV isolates to AZT.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

SUNY / Health Sciences Ctr at Brooklyn

🇺🇸

Brooklyn, New York, United States

Baystate Med Ctr of Springfield

🇺🇸

Springfield, Massachusetts, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

Kaiser Permanente Franklin Med Ctr

🇺🇸

Denver, Colorado, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

Children's Mem Hosp Family Cln / Northwestern Univ Med Schl

🇺🇸

Chicago, Illinois, United States

Rush Presbyterian - Saint Luke's Med Ctr

🇺🇸

Chicago, Illinois, United States

Northwestern Univ Med School

🇺🇸

Chicago, Illinois, United States

Cook County Hosp

🇺🇸

Chicago, Illinois, United States

Univ of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

SUNY / State Univ of New York

🇺🇸

Syracuse, New York, United States

Univ of Washington

🇺🇸

Seattle, Washington, United States

Univ of Nebraska Med Ctr

🇺🇸

Omaha, Nebraska, United States

Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium

🇺🇸

San Jose, California, United States

San Mateo AIDS Program / Stanford Univ

🇺🇸

Stanford, California, United States

SUNY / Erie County Med Ctr at Buffalo

🇺🇸

Buffalo, New York, United States

Univ of Rochester Medical Center

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath